Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MiNK Therapeutics, Inc. (INKT)

MiNK Therapeutics Q2 net loss narrows to $3.1 million from $4.2 million

Positive Impact 3 of 5 earnings Written later

MiNK Therapeutics reported second-quarter 2026 results, with a net loss of $3.1 million, or $0.62 per share, compared with $4.2 million, or $1.06 per share, a year earlier. Cash and cash equivalents fell to $8.8 million as of June 30, 2026, down from $13.4 million at December 31, 2025, which matters to shareholders because it reflects the company's funding position.

Key points

  • Q2 2026 net loss was $3.1 million ($0.62 per share), down from $4.2 million ($1.06 per share) in Q2 2025.
  • Six-month net loss was $5.9 million ($1.20 per share), compared with $7.0 million ($1.76 per share) a year earlier.
  • Cash and cash equivalents were $8.8 million at June 30, 2026, versus $9.5 million at March 31, 2026 and $13.4 million at December 31, 2025.
  • The company attributes the year-over-year improvement to expense discipline; additional data from the C-1300-02 trial are expected in early 2027.

The filing

CompanyMiNK Therapeutics, Inc. (INKT)
Form8-K, current report
Filed with the SECAug 13, 2026, 7:40 AM ET
Accession number0001193125-26-347907

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.